Drug class
Direct, reversible intravenous P2Y12 platelet ADP-receptor antagonist; antiplatelet agent
Mechanism of action
Directly and reversibly blocks platelet P2Y12 receptors, preventing ADP-mediated activation of the glycoprotein IIb/IIIa complex and platelet aggregation. Its rapid onset and short offset are related to its intravenous administration and rapid plasma clearance.
General use cases
- Adjunct to percutaneous coronary intervention (PCI) to reduce periprocedural myocardial infarction, repeat coronary revascularisation and stent thrombosis in patients not treated with an oral P2Y12 inhibitor and not receiving a glycoprotein IIb/IIIa inhibitor
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
